Radioactive microspheres aim to shrink stubborn liver tumors

NCT ID NCT07657273

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can safely shrink tumors and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NRT6003 (yttrium-90 carbon microspheres)
What this could lead to: If it works, this could offer a new way to control liver tumors that haven't responded to earlier treatments, potentially shrinking them and improving outcomes.
What could go wrong: This is a small, early-phase study with only 20 people, so results may not apply widely. The treatment involves radiation and could cause side effects like liver damage or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

The Second Affiliated Hospital, Guangzhou Medical University

Guangzhou, Guangdong, 510260, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.